Matrix Laboratories Receives Tentative FDA Approval to Provide Generic ARV Under PEPFAR
October 6, 2010
Pharmaceutical company Mylan announced on Tuesday that its "subsidiary Matrix Laboratories Ltd. has received tentative government approval for atazanavir sulfate capsules, an AIDS treatment that will be available in some developing countries," Pittsburgh Business Times reports. "Atazanavir sulfate capsules are the generic version of Bristol Myers Squibb's Reyataz capsules, which are used in combination with other medications to control HIV infection. ... The Food and Drug Administration approved Matrix's application for the product under" PEPFAR, the article continues (10/5). In a press release, Mylan President Heather Bresch said, "This approval is yet another step in improving access to quality, affordable treatment for people living with HIV/AIDS in developing countries. Atazanavir has a distinct resistance profile compared with other protease inhibitors and is an important addition to the product portfolio being made available to patients in developing countries" (10/5).
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)